Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.
The deal for $38.25 per share represents a premium of 79.7% to Dicerna's closing price on Wednesday.
The two companies have been in a research collaboration since 2019 to develop multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.
Novo Nordisk expects to initiate clinical development of the first investigational therapeutic to emerge from this collaboration in 2022.